1. Twenty-one patients with post-traumatic stress disorder (PTSD) were included in a study utilizing baseline rapid eye movement (REM) latency measurements, the dexamethasone suppression test (DST), and the protirelin (thyroid releasing hormone; TRH) stimulation test. The DST and TRH stimulation test were repeated after double blind treatment with desipramine. 2. A high number of patients (75%) exhibited a REM latency of 60 min or less and blunted thyroid stimulating hormone (TSH) response to TRH (61.9%) on baseline tests while only one patient showed cortisol escape from dexamethasone suppression. 3. After four weeks of desipramine treatment, significant improvements were reported in the Hamilton Rating Scale for depression, but not for anxiety symptoms, PTSD symptoms, or self-rated depressive symptoms. 4. Desipramine treatment did not affect hormonal responses to TRH. 5. The findings of shortened REM latency and altered TRH stimulation test suggest PTSD and depression may share some pathophysiological abnormalities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0278-5846(95)00024-p | DOI Listing |
Sleep Med
December 2024
Eisai Inc., 200 Metro Blvd, Nutley, NJ, 07110, USA.
Objective/background: Comorbid insomnia with obstructive sleep apnea (COMISA) is associated with worse daytime function and more medical/psychiatric comorbidities vs either condition alone. COMISA may negatively impact sleep duration and reduce rapid eye movement (REM) sleep, thereby impairing cognition. These post-hoc analyses evaluated the effect of lemborexant (LEM), a dual-orexin-receptor antagonist approved for adults with insomnia, on sleep architecture in participants with COMISA.
View Article and Find Full Text PDFAlzheimers Dement
January 2025
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
Introduction: Sleep disturbances are associated with Alzheimer's disease (AD) and Alzheimer's disease and related dementias (ADRD), but the relationship between sleep architecture, particularly rapid eye movement (REM) sleep, and AD/ADRD biomarkers remains unclear.
Methods: We enrolled 128 adults (64 with Alzheimer's disease, 41 with mild cognitive impairment [MCI], and 23 with normal cognition [NC]), mean age 70.8 ± 9.
Sleep Breath
January 2025
Soroka Medical Center, Yitzhack I. Rager Blvd. 151, Be'er Sheva, Israel.
Purpose: This study aimed to validate the new DormoTech Vlab device's performance, usability, and validity as a sleep test and physiological data recorder. The novel device has been designed for patient comfort, ease of use, and home-based assessment of sleep disordered breathing and other sleep-related measurements.
Methods: Forty-seven adults (mean age = 52 years, 42% female, body mass index 29.
Eur J Neurosci
January 2025
Institute of Physiology, Sleep Research & Clinical Chronobiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Timing and architecture of sleep are co-driven by circadian rhythms modulated by their major Zeitgeber light and darkness. In a natural environment, one is exposed to 3.000 lx (cloudy winter sky) to 100.
View Article and Find Full Text PDFWorld J Psychiatry
January 2025
Sleep Psychosomatic Medicine Center, Taihe Hospital of Shiyan City, Affiliated Hospital of Hubei University of Medicine, Shiyan 442000, Hubei Province, China.
Background: Mild cognitive impairment (MCI) has a high risk of progression to Alzheimer's disease. The disease is often accompanied by sleep disorders, and whether sleep disorders have an effect on brain function in patients with MCI is unclear.
Aim: To explore the near-infrared brain function characteristics of MCI with sleep disorders.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!